Numerous studies have demonstrated that FGF21 is effective in ameliorating the metabolic syndrome, lowering LDL‐C and improving other related diseases and conditions such as type 2 diabetes, non‐alcoholic steatohepatitis, obesity and chronic inflammation.36, 38, 39 We have found FGF21 to be able to cause a marked improvement in the lipo‐profiles (reducing LDL‐C and elevating HDL‐C) and prevent AS in ApoE−/− mice. The gene discussed is FGF21; the disease is obesity due to melanocortin 4 receptor deficiency.